- Session times are Korea Standard Time (UTC/GMT+9). Please click the link and check your local time.
- Program is subject to change.
- Some sessions are in Korean.
Please click “Session Code” for the detailed program.
| Time | Channel 1 | Channel 2 | Channel 3 |
|---|---|---|---|
| 10:30-11:00 | Opening Ceremony | ||
| 11:00-12:00 | PL01 | ||
| The current status of creatinine standardization in Korea |
|||
| 12:00-12:30 | EW01 | EW02 | EW03 |
 Evidence-based update on rapid molecular and antigen COVID-19 tests |
 Recent advances in the laboratory diagnosis of drug-resistant Tuberculosis |
 Automated Real-Time RT-PCR solution with the high-throughput system for COVID-19 testing in clinical practice |
|
| 12:30-12:40 | Break | ||
| 12:40-13:20 | KS01 | ||
| Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection | |||
| 13:20-13:30 | Break | ||
| 13:30-14:00 | EW04 | EW05 | EW06 |
 Novel insight for complete management of gastrointestinal infection |
 New marker “URD” validation to identify glomerular origin hematuria |
 Covi-FERON: Interferon-Gamma release assay for checking SARS-CoV-2 specific T cell immunity |
|
| 14:00-15:30 | SY01 | SY02 | SY03 (Kor) |
| Hereditary breast cancer | Practical aspects of laboratory management (IX) : Introduction of the essential concepts for practical laboratory management | *지도전문의 필수 교육 (14:00-18:00) Education course for laboratory medicine specialist |
|
| 15:30-15:40 | Break | ||
| 15:40-17:10 | SY04 | SY05 | |
| The role of clinical microbiology in COVID-19 control | Tests for diagnosing and monitoring chronic kidney disease |
||
| 17:10-17:20 | Break | ||
| 17:20-18:00 | |||
| Time | Channel 1 | Channel 2 | Channel 3 |
|---|---|---|---|
| 08:00-09:30 | SY06 | SY07 | SY08 (Kor) |
| AACC-KSLM Session Data aggregation and integration in laboratory medicine: How to build prediction models and learn from multi-institutional data |
CLSI-KSLM Session Essential CLSI guidelines for good laboratory practice |
Education workshop for residents and new specialists in laboratory medicine | |
| 09:30-09:40 | Break | ||
| 09:40-10:40 | OP01 | OP02 | OP03 |
| Clinical Chemistry, Diagnostic Immunology | Diagnostic Genetics, Diagnostic Hematology | Clinical Microbiology, General Laboratory Medicine, Transfusion Medicine | |
| 10:40-11:00 | Break | ||
| 11:00-12:00 | PL02 | ||
| AACC-KSLM Session Big data and AI in laboratory medicine: Progress and challenges |
|||
| 12:00-12:30 | EW07 | EW08 | EW09 |
 Clinical utility of anti-SARS-CoV-2 serology assays |
 Laboratory Efficiency: Driving faster TAT for clinical chemistry and gaining effective use of resources |
 Introduction of PIK3CA mutation testing in plasma in cancer patients. Molecular target or prognostic factor? |
|
| 12:30-12:40 | Break | ||
| 12:40-13:20 | KS02 | ||
| Scientific uncertainties during the COVID-19 pandemic and challenges for the future | |||
| 13:20-13:30 | Break | ||
| 13:30-14:00 | EW10 | EW11 | EW12 |
Analytical performance evaluation and workflow analysis of coagulation analyzer Roche Cobas t-511 |
 IL-6, PCT and high sensitivity troponin in critical care disease management |
 Improving the management of patients with sepsis: Experience with a blood culture diagnostic clinical trial |
|
| 14:00-15:30 | SY09 | SY10A | SY11 (Kor) |
| Challenges in the coagulation laboratory | Asia Session COVID-19 laboratory diagnosis in Asian countries |
*감염관리 필수교육 (14:00-16:00) COVID-19 and infection control |
|
| 15:30-15:40 | |||
| 15:40-17:10 | SY12 | ||
| SY10B | |||
| Current management of chronic hepatitis B infection and future aspects of immunologic diagnostic approach |
|||
| (15:50-17:10) Asia Session COVID-19 laboratory diagnosis in Asian countries |
|||
| 17:10-17:20 | Break | ||
| 17:20-18:00 | KS03 | ||
| Neutralizing antibodies and COVID-19: Vaccine, VOCs and immune longevity | |||
| Time | Channel 1 | Channel 2 | Channel 3 | |
|---|---|---|---|---|
| 09:00-10:30 | SY13 | SY14 (Kor) | Senate Meeting (09:00-12:00) |
|
| CAP-KSLM Session Cardiac markers 2021 |
KDCA-KSLM Session Strengthening public-private cooperation in laboratory medicine for infectious diseases in the post-COVID era |
|||
| 10:30-11:00 | Break | |||
| 11:00-12:00 | PL03 | |||
| Molecular point of care testing for infectious diseases | ||||
| 12:00-12:30 | EW13 | |||
 Laboratory medicine and healthcare excellence; Till death do us part |
||||
| 12:30-12:40 | Break | |||
| 12:40-13:20 | KS04 | |||
| How to implement a PBM program at your hospital | ||||
| 13:20-13:30 | Break | |||
| 13:30-14:00 | EW14 | EW15 | ||
 AdvanSure SARS-CoV-2 IgG ELISA for monitoring immune response after infection or vaccination |
 Development and evaluation of AccuPower® COVID-19 Kit for SARS-CoV-2 detection in Sputum and NPS/OPS, saliva and pooled samples |
|||
| 14:00-15:30 | SY15 | SY16 (Kor) | SY17 (Kor) | |
| A novel cellular immunotherapy in cancer: CAR-T cell, CAR-NK cell, GMP | MFDS-KSLM Session Post-market surveillance and renewal system in MFDS |
Inspector workshop of Korean laboratory accreditation program | ||
| 15:30-15:40 | Break | |||
| 15:40-16:10 | KSLM General Assembly | |||
